This study is looking at the safety of the Herpes Zoster Subunit (HZ/su) Vaccine, which helps prevent shingles, in people with Systemic Lupus Erythematosus (SLE). Researchers want to see if this vaccine is as safe as a placebo (a saline injection) for people with lupus, specifically regarding the risk of moderate or severe lupus flares. They also want to see how well the vaccine helps the immune system in people with lupus. You may be able to join if you are 18 to 90 years old and have been diagnosed with SLE. The study aims to enroll 224 participants. The current status of the study is unclear.

Study design

This is a randomized, double-blind, placebo-controlled crossover study, meaning participants will be randomly assigned to receive either the vaccine or a placebo, and neither you nor your doctor will know which you receive. The study plans to enroll 224 participants.

What's involved

You would receive two injections of either the vaccine or a placebo, given at specific times (weeks 0 and 8 or weeks 24 and 32).

Compensation

Not stated in the trial record.

Follow-up

Researchers will monitor you for moderate or severe lupus flares for up to 48 weeks after your first dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.